ES2628005T3 - 2,3-Benzodiazepinas - Google Patents

2,3-Benzodiazepinas Download PDF

Info

Publication number
ES2628005T3
ES2628005T3 ES13748072T ES13748072T ES2628005T3 ES 2628005 T3 ES2628005 T3 ES 2628005T3 ES 13748072 T ES13748072 T ES 13748072T ES 13748072 T ES13748072 T ES 13748072T ES 2628005 T3 ES2628005 T3 ES 2628005T3
Authority
ES
Spain
Prior art keywords
alkyl
alkoxy
amino
hydroxy
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13748072T
Other languages
English (en)
Inventor
Stephan Siegel
Stefan BÄURLE
Arwed Cleve
Bernard Haendler
Amaury Ernesto FERNANDEZ-MONTALVAN
Ursula MÖNNING
Sabine Krause
Pascale Lejeune
Norbert Schmees
Matthias BUSEMANN
Simon Holton
Joachim Kuhnke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48979774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2628005(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2628005T3 publication Critical patent/ES2628005T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula general I **Fórmula** A en la que X representa un átomo de oxígeno o de azufre, y A representa un anillo de heteroarilo monocíclico con 5 o 6 átomos de anillo o representa un anillo de fenilo, y R1a representa hidrógeno, halógeno, ciano, carboxi, amino o aminosulfonilo, o representa un resto alcoxi C1-C6, alcoxi C1-C3-alquilo C1-C3, alcoxi C1-C3-alcoxi C2-C3, alquil C1-C6-amino, alquil C1-C6-carbonilamino, alquil C1-C6-amino-alquilo C1-C6, N-(heterociclil)-alquilo C1-C6, N-(heterociclil)-alcoxi C1-C6, hidroxi-alquilo C1-C6, hidroxi-alcoxi C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, alquil C1-C6-carbonilo o alcoxi C1- C6-carbonilo, orepresenta un resto heterociclilo monocíclico con 3 a 8 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, ciano, nitro, hidroxi, amino, oxo, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, hidroxi-alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, alquil C1-C6-amino-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3-C10, fenilo, halofenilo, fenil-alquilo C1-C6, piridinilo, -NR6C(>=O)-R9, -C(>=O)-NR6R7, -C(>=O)-R8, -S(>=O)2-NR6R7, -S(>=O)-R9, -S(>=O)2-R9, -NH-S(>=O)2-R9 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representa un resto heteroarilo monocíclico con 5 o 6 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, hidroxi, amino, ciano, nitro, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, alquil C1-C6-amino-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3-C10, -C(>=O)-NR6R7, -C(>=O)-R8, -S(>=O)2-NR6R7, -S(>=O)-R9, - S(>=O)2-R9, -NH-S(>=O)2-R9 y/o con un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, y/o con un resto heteroarilo monocíclico con 5 o 6 átomos de anillo, y/o con un resto fenilo, que a su vez puede estar sustituido dado el caso una o varias veces, de manera igual o diferente, con halógeno, alquilo C1-C3 y/o alcoxi C1-C3, o representa un resto fenilo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1- C6, alquil C1-C6-amino, amino-alquilo C1-C6, alquil C1-C6-amino-alquilo C1-C6, -C(>=O)NR6R7, -C(>=O)R8, alquil C1- C3-sulfinilo, alquil C1-C3-sulfonilo, -S(>=O)2NH2, alquil C1-C3-sulfonilamino, alquil C1-C3-aminosulfonilo, cicloalquil C3-C6-aminosulfonilo, halo-alquilo C1-C6, halo-alcoxi C1-C6, hidroxi-alquilo C1-C6, cicloalquilo C3-C10 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo y/o un resto heteroarilo monocíclico con 5 o 6 átomos de anillo, que a su vez dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, alquilo C1-C3 y/o alcoxi C1-C3, y R1b y R1c representan, independientemente entre sí, hidrógeno, halógeno, hidroxi, ciano, nitro y/o representan un resto alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3- C10 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, y R2 representa un resto alquilo C1-C3 o trifluorometilo o cicloalquilo C3 o C4, y R3 representa ciclopropilo, alquilo C1-C3, alcoxi C1-C3, amino, ciclopropilamino o alquil C1-C3-amino, y R4 y R5 representan, independientemente entre sí, hidrógeno, hidroxi, ciano, nitro, amino, aminocarbonilo, flúor, cloro, bromo, alquilo C1-C6, alcoxi C1-C6, alquil C1-C6-amino, alquil C1-C6-carbonilamino, alquil C1-C6- aminocarbonilo o alquil C1-C6-aminosulfonilo, o representan alquilo C1-C6, alcoxi C1-C6, alquil C1-C6-amino, alquil C1-C6-carbonilamino, alquil C1-C6- aminocarbonilo o alquil C1-C6-aminosulfonilo que dado el caso pueden estar sustituidos una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, carboxi, hidroxi-alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6- alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, heterociclilo monocíclico con 3 a 8 átomos de anillo y/o heteroarilo monocíclico con 5 o 6 átomos de anillo, pudiendo estar los restos heterociclilo y heteroarilo monocíclicos mencionados a su vez dado el caso sustituidos una vez con alquilo C1-C3, o representan cicloalquilo C3-C10 que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, alquil C1- C6-amino, amino-alquilo C1-C6, alquil C1-C6-amino-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan heteroarilo monocíclico con 5 o 6 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, hidroxi-alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, alquil C1-C6- amino-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3-C10, -C(>=O)R8, -S(>=O)2R9, -NR6R7 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan heterociclilo monocíclico con 3 a 8 átomos de anillo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, oxo, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, alquil C1-C6-amino-alquilo C1-C6, hidroxi-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3-C10, -C(>=O)R8, -S(>=O)2R9, -NR6R7 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, o representan fenilo que dado el caso puede estar sustituido una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, ciano, nitro, carboxi, alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, alquil C1-C6- amino, amino-alquilo C1-C6, alquil C1-C6-aminocarbonilo, alquil C1-C6-aminosulfonilo, alquil C1-C6-amino-alquilo C1-C6, hidroxi-alquilo C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, cicloalquilo C3-C10 y/o un resto heterociclilo monocíclico con 3 a 8 átomos de anillo, y R6 y R7 representan, independientemente entre sí, hidrógeno, alquilo C1-C3, ciclopropilo, di-alquil C1-C3-amino-alquilo C1-C3 o fluoropiridilo, y R8 representa hidroxi, alquilo C1-C6, halo-alquilo C1-C3, hidroxi-alquilo C1-C3, alcoxi C1-C3-alquilo C1-C3, 30 cicloalquilo C3-C8, fenilo, heterociclilo monocíclico con 3 a 8 átomos de anillo o heteroarilo monocíclico con 5 o 6 átomos de anillo, pudiendo estar fenilo, heteroarilo y heterociclilo dado el caso sustituidos una o dos veces con halógeno, alcoxi C1-C3 o alquilo C1-C3, y R9 representa hidrógeno, alquilo C1-C6 o alcoxi C1-C4, así como sus polimorfos, enantiómeros, diaestereómeros, racematos, tautómeros, solvatos, sales fisiológicamente aceptables y solvatos de estas sales, con la condición de que si A representa un anillo de fenilo y R4 y R5 representan, independientemente entre sí, hidrógeno, hidroxi, ciano, nitro, amino, aminocarbonilo, flúor, cloro, bromo, alquilo C1-C6, alcoxi C1-C6, alquil C1-C6-amino, alquil C1-C6- carbonilamino, alquil C1-C6-aminocarbonilo o alquil C1-C6-aminosulfonilo, o representan alquilo C1-C6, alcoxi C1-C6, alquil C1-C6-amino, alquil C1-C6-carbonilamino, alquil C1-C6-aminocarbonilo o alquil C1-C6-aminosulfonilo que dado el caso pueden estar sustituidos una o varias veces, de manera igual o diferente, con halógeno, amino, hidroxi, carboxi, hidroxi-alquilo C1-C6, alcoxi C1-C6, alcoxi C1-C6-alquilo C1-C6, alquil C1-C6-amino, amino-alquilo C1-C6, heterociclilo monocíclico con 3 a 8 átomos de anillo y/o heteroarilo monocíclico con 5 o 6 átomos de anillo, pudiendo estar los restos heterociclilo y heteroarilo monocíclicos mencionados a su vez dado el caso sustituidos una vez con alquilo C1-C3, R1a no representa hidrógeno, halógeno, ciano, carboxi, amino o aminosulfonilo, o representa un resto alcoxi C1-C6, alcoxi C1-C3-alquilo C1-C3, alcoxi C1-C3-alcoxi C2-C3, alquil C1-C6-amino, alquil C1-C6-carbonilamino, alquil C1-C6- amino-alquilo C1-C6, N-(heterociclil)-alquilo C1-C6, N-(heterociclil)-alcoxi C1-C6, hidroxi-alquilo C1-C6, hidroxi-alcoxi C1-C6, halo-alquilo C1-C6, halo-alcoxi C1-C6, alquil C1-C6-carbonilo o alcoxi C1-C6-carbonilo, y no comprendiendo la condición aquellos compuestos de fórmula general (I) en la que A representa fenilo y R4 representa hidrógeno, flúor, cloro o bromo y R5 representa alcoxi C1-C6 que está sustituido una o varias veces, de manera igual o diferente, con halógeno y R1a representa halógeno, y tampoco aquellos compuestos de fórmula general (I) en la que A representa fenilo y R4 representa hidrógeno y R5 representa alcoxi C1-C6 que está sustituido una o varias veces, de manera igual o diferente, con un resto heterociclilo monocíclico con 3 a 8 átomos de anillo y/o un resto heteroarilo monocíclico con 5 o 6 átomos de anillo, pudiendo estar los restos heterociclilo y heteroarilo monocíclicos mencionados a su vez dado el caso sustituidos una vez con alquilo C1-C3, y R1a representa halógeno.
ES13748072T 2012-08-16 2013-08-13 2,3-Benzodiazepinas Active ES2628005T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012214602 2012-08-16
DE102013202104 2013-02-08
PCT/EP2013/066931 WO2014026997A1 (de) 2012-08-16 2013-08-13 2,3-benzodiazepine

Publications (1)

Publication Number Publication Date
ES2628005T3 true ES2628005T3 (es) 2017-08-01

Family

ID=48979774

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13748072T Active ES2628005T3 (es) 2012-08-16 2013-08-13 2,3-Benzodiazepinas

Country Status (22)

Country Link
US (1) US9890147B2 (es)
EP (1) EP2885286B1 (es)
JP (1) JP6333251B2 (es)
KR (1) KR20150041787A (es)
CN (1) CN104755473B (es)
AR (1) AR092129A1 (es)
AU (1) AU2013304146A1 (es)
CA (1) CA2881996A1 (es)
CL (1) CL2015000337A1 (es)
CR (1) CR20150066A (es)
DO (1) DOP2015000022A (es)
EA (1) EA201590356A1 (es)
EC (1) ECSP15005376A (es)
ES (1) ES2628005T3 (es)
IL (1) IL236898A0 (es)
MX (1) MX2015001880A (es)
PE (1) PE20150729A1 (es)
PH (1) PH12015500323A1 (es)
TN (1) TN2015000051A1 (es)
TW (1) TW201408651A (es)
UY (1) UY34977A (es)
WO (1) WO2014026997A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
SG11201505979UA (en) * 2013-02-19 2015-09-29 Bayer Pharma AG Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015121226A1 (de) * 2014-02-13 2015-08-20 Bayer Pharma Aktiengesellschaft 6-substituierte 2,3-benzodiazepine
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
CA3000633C (en) 2014-10-14 2023-10-03 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
WO2016062688A1 (de) * 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-phenyl-4,5-dihydro-3h-2,3-benzodiazepine derivatives
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2017005711A1 (de) * 2015-07-09 2017-01-12 Bayer Pharma Aktiengesellschaft Phosphor- und schwefel-substituierte benzodiazepin-derivate
WO2017063959A1 (de) * 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft N-sulfoximinophenyl-substituierte benzodiazepin-derivate als bet-proteininhibitoren
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10167293B2 (en) * 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
JP7036796B2 (ja) 2016-08-15 2022-03-15 ジボダン エス エー 有機化合物
CN109406685B (zh) * 2018-12-27 2021-05-25 湖南泰新医药科技有限公司 一种分离卡非佐米和其异构体的高效液相色谱方法
US20220079952A1 (en) * 2019-05-24 2022-03-17 Emory University Uses of Radiation and Benzodiazepine Derivatives in Cancer Therapies
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
CN114920727B (zh) * 2022-05-26 2023-07-25 重庆华邦制药有限公司 一种卢帕他定的制备方法
WO2023229535A1 (en) 2022-05-27 2023-11-30 Engine Biosciences Pte. Ltd. Bet polypeptide therapeutic agents for generating synthetic lethality in tumors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3483186A (en) * 1966-11-22 1969-12-09 Mcneilab Inc 2-benzazepine derivatives
HU208429B (en) 1991-05-03 1993-10-28 Gyogyszerkutato Intezet Process for producing 1-/3-chloro-phenyl/-4-methyl-7,8-dimethoxy-5h-2,3-benzodiazepine of high purity
EP0638560A4 (en) 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
WO1994006802A1 (fr) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
EP0703222A1 (en) 1993-05-13 1996-03-27 Yoshitomi Pharmaceutical Industries, Ltd. 3-aminoazepine compound and pharmaceutical use thereof
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) * 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
CA2258053A1 (en) 1996-06-12 1997-12-18 Yoshihisa Yamamoto Cytokine production inhibitors, triazepine compounds, and intermediates thereof
CN1109037C (zh) 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
WO2001098280A2 (en) 2000-06-16 2001-12-27 Annovis, Inc. 5h-2,3-benzodiazepine antagonists of excitatory amino acid receptors
HU225100B1 (hu) * 2000-12-21 2006-06-28 Egyt Gyogyszervegyeszeti Gyar 2,3-Benzodiazepinszármazékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények és alkalmazásuk
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US6858605B2 (en) * 2003-02-04 2005-02-22 Ivax Drug Research Institute, Ltd. Substituted 2,3-benzodiazepine derivatives
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
GB0503962D0 (en) 2005-02-25 2005-04-06 Kudos Pharm Ltd Compounds
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
EA016087B1 (ru) * 2005-12-30 2012-02-28 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Оптические изомеры дигидро-2,3-бензодиазепинов и их стереоселективный синтез
DE102006042439A1 (de) 2006-09-09 2008-03-27 Saltigo Gmbh Verfahren zur katalytischen Herstellung von aromatischen oder heteroaromatischen Nitrilen
TW200902024A (en) * 2007-04-02 2009-01-16 Teva Pharma Novel 2,3-benzodiazepine derivatives and their use as antipsychotic agents
JP2008308491A (ja) * 2007-05-11 2008-12-25 Gunma Univ がん治療用の遊走阻害剤
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
JP5442021B2 (ja) * 2009-09-28 2014-03-12 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩ならびに農園芸用殺菌剤
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2881996A1 (en) 2014-02-20
DOP2015000022A (es) 2015-09-15
JP2015529192A (ja) 2015-10-05
US9890147B2 (en) 2018-02-13
EA201590356A1 (ru) 2015-07-30
MX2015001880A (es) 2015-05-11
EP2885286B1 (de) 2017-03-22
CL2015000337A1 (es) 2015-05-04
HK1208443A1 (en) 2016-03-04
ECSP15005376A (es) 2015-12-31
TW201408651A (zh) 2014-03-01
AR092129A1 (es) 2015-03-25
WO2014026997A1 (de) 2014-02-20
CR20150066A (es) 2015-04-17
PH12015500323A1 (en) 2015-03-30
CN104755473B (zh) 2017-03-08
JP6333251B2 (ja) 2018-05-30
KR20150041787A (ko) 2015-04-17
AU2013304146A1 (en) 2015-02-26
UY34977A (es) 2014-03-31
CN104755473A (zh) 2015-07-01
EP2885286A1 (de) 2015-06-24
TN2015000051A1 (en) 2016-06-29
IL236898A0 (en) 2015-03-31
PE20150729A1 (es) 2015-06-14
US20150203483A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
ES2628005T3 (es) 2,3-Benzodiazepinas
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1124737T1 (el) Ανταγωνιστες lpa
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
MX2018010191A (es) Inhibidores de glucosidasa.
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
MX2017002670A (es) Inhibidores de glucosidasa.
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2020004504A (es) Derivados de fenoximetilo.
ECSP18083519A (es) Inhibidores de bromodominios
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
CY1120619T1 (el) Χημικες οντοτητες
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MX389265B (es) Aminopirimidinas como inhibidores de alk.
EA201891780A1 (ru) Производные сульфонамида и содержащие их фармацевтические композиции
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης
PE20190376A1 (es) Combinaciones farmaceuticas para el tratamiento del cancer